Should You Buy Taysha Gene Therapies Inc (TSHA) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
4.570
1 Day change
2.01%
52 Week Range
6.020
Analysis Updated At
2026/01/26
Taysha Gene Therapies Inc (TSHA) is not a strong buy for a beginner, long-term investor at this moment. While analysts have a positive outlook with raised price targets and hedge funds are increasing their positions, the technical indicators are neutral to bearish, and the financial performance shows significant challenges. Additionally, the lack of recent news or significant positive catalysts makes it prudent to hold off on investing right now.
Technical Analysis
The MACD is negative and expanding (-0.0587), indicating bearish momentum. RSI is neutral at 39.268, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level (4.81), with support at 4.509 and resistance at 5.112. The technical indicators suggest a weak or neutral trend.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Technical Summary
Sell
7
Buy
4
Positive Catalysts
Analysts are optimistic about the company's progress in its Rett syndrome study, with multiple raised price targets and Overweight ratings. Hedge funds are significantly increasing their positions, indicating institutional confidence.
Neutral/Negative Catalysts
The company's financials are weak, with revenue dropping to zero and a negative net income of -$32.73M. Technical indicators show no clear upward momentum, and the stock has a 70% chance of declining in the short term. No recent news or congress trading data is available to suggest immediate positive catalysts.
Financial Performance
In Q3 2025, revenue dropped to $0 (-100% YoY), net income improved to -$32.73M (+28.24% YoY), EPS decreased to -0.09 (-10% YoY), and gross margin remained at 100%. The financials indicate significant challenges, particularly with no revenue generation.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts are bullish on TSHA, with multiple firms raising price targets (e.g., Wells Fargo to $11, Cantor Fitzgerald to $19) and maintaining Overweight or Buy ratings. The focus is on the company's progress in its Rett syndrome study, which is seen as a potential long-term growth driver.
Wall Street analysts forecast TSHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TSHA is 11.6 USD with a low forecast of 8 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast TSHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TSHA is 11.6 USD with a low forecast of 8 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.480
Low
8
Averages
11.6
High
19
Current: 4.480
Low
8
Averages
11.6
High
19
Wells Fargo
Zachary Fadem
Overweight
maintain
$8 -> $11
AI Analysis
2026-01-05
Reason
Wells Fargo
Zachary Fadem
Price Target
$8 -> $11
AI Analysis
2026-01-05
maintain
Overweight
Reason
Wells Fargo analyst Zachary Fadem raised the firm's price target on Taysha Gene Therapies to $11 from $8 and keeps an Overweight rating on the shares. The firm sees another year of outperformance for the stock, driven by continued momentum in the company's pivotal Rett syndrome study following last year's alignment with FDA on a favorable design.
Goldman Sachs
Salveen Richter
Early-Stage Biotech -> Buy
upgrade
$11
2025-12-04
Reason
Goldman Sachs
Salveen Richter
Price Target
$11
2025-12-04
upgrade
Early-Stage Biotech -> Buy
Reason
Goldman Sachs analyst Salveen Richter moved its rating on Taysha Gene Therapies to Buy with an $11 price target from Early-Stage Biotech designation. The firm is positive on the company's outlook in Rett syndrome. believe Taysha can achieve the response rate of 33% needed to meet the minimum threshold for success in the REVEAL study, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TSHA
